Overview

RPE65 Gene Therapy （LX101）for Leber's Congenital Amaurosis

Status:
Not yet recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether gene transfer(LX101) will be safe and effective in the treatment of Leber Congenital Amaurosis (LCA).

Phase:

N/A

Details

Lead Sponsor:

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine